Pharmaceuticals
US Obesity Drugs Market Analysis
The US obesity drugs market is projected to grow from $1.2 Bn in 2022 to $5.2 Bn by 2030, registering a CAGR of 20.3% during the forecast period of 2022-30. There is increasing awareness of the health risks associated with obesity, including heart disease, diabetes, and high blood pressure. This is driving demand for effective treatments that can help reduce the risk of these conditions. Novo Nordisk, a Danish pharmaceutical company is a major player in the obesity drugs market, with a portfolio of products that includes Saxenda (liraglutide), an injectable drug approved for weight loss in adults with obesity.
Buy Now
US Obesity Drugs Market Executive Summary
The US obesity drugs market is projected to grow from $1.2 Bn in 2022 to $5.2 Bn by 2030, registering a CAGR of 20.3% during the forecast period of 2022-30.
The US obesity drugs market refers to the pharmaceutical industry that produces and sells drugs used for the treatment of obesity, a medical condition characterized by excess body fat that can lead to health problems such as heart disease, diabetes, and high blood pressure.
The market is relatively small compared to other pharmaceutical sectors, but it has been growing steadily in recent years due to the increasing prevalence of obesity in the US population. According to the Centers for Disease Control and Prevention (CDC), over 42% of American adults were considered obese in 2018.
There are currently a limited number of prescription drugs approved by the US Food and Drug Administration (FDA) for the treatment of obesity. These drugs work by suppressing appetite, increasing feelings of fullness, or reducing the absorption of fat in the body. The most commonly prescribed drugs include phentermine, liraglutide, and orlistat.
Despite the availability of these drugs, obesity remains a significant public health problem in the US. This is partly due to the limited efficacy of the drugs, as well as the high cost and potential side effects associated with their use. As a result, many individuals with obesity turn to alternative treatments such as diet and exercise or weight loss surgery.
Overall, the US obesity drugs market is expected to continue growing in the coming years as the prevalence of obesity increases and new drugs are developed and approved by regulatory agencies. However, the market is also likely to face challenges such as increased competition and regulatory scrutiny, as well as ongoing concerns about the safety and efficacy of obesity drugs.
Market Dynamics
There are several key drivers of the US obesity drugs market:
- Increasing Prevalence of Obesity: The prevalence of obesity in the US population has been increasing steadily, which is driving demand for obesity drugs. According to the CDC, over 42% of American adults were considered obese in 2018.
- Rising Healthcare Costs: Obesity is a major contributor to healthcare costs in the US, and there is a growing need for effective treatments that can help reduce these costs. Obesity-related healthcare costs are estimated to be around $190 Bn per year in the US.
- Advances in Drug Development: There has been significant progress in the development of new obesity drugs in recent years, which is increasing the number of treatment options available to patients.
- Growing Awareness of the Health Risks of Obesity: There is increasing awareness of the health risks associated with obesity, including heart disease, diabetes, and high blood pressure. This is driving demand for effective treatments that can help reduce the risk of these conditions.
- Increasing Focus on Preventive Healthcare: There is a growing focus on preventive healthcare in the US, which is leading to greater investment in treatments and interventions that can help prevent or manage chronic conditions such as obesity.
- Strong Regulatory Environment: The US has a strong regulatory environment for pharmaceuticals, which helps ensure the safety and efficacy of obesity drugs. This regulatory environment also helps to build trust in the market among patients, healthcare providers, and investors.
Overall, these drivers are likely to continue to fuel growth in the US obesity drugs market in the coming years. However, there are also challenges and risks associated with this market, such as regulatory hurdles, pricing pressures, and concerns about the safety and efficacy of new drugs.
Competitive Landscape
Key Players
Some of the key players in the US obesity drugs market include:
- Novo Nordisk: This Danish pharmaceutical company is a major player in the obesity drugs market, with a portfolio of products that includes Saxenda (liraglutide), an injectable drug approved for weight loss in adults with obesity
- Eisai: Eisai is a Japanese pharmaceutical company that markets Belviq (lorcaserin), an oral weight loss drug that works by suppressing appetite. However, the drug was voluntarily withdrawn from the US market in 2020 due to safety concerns
- Takeda: Takeda is a Japanese pharmaceutical company that markets Contrave (naltrexone/bupropion), an oral weight loss drug that works by suppressing appetite and reducing food cravings
- Roche: Roche is a Swiss pharmaceutical company that markets Xenical (orlistat), an oral weight loss drug that works by inhibiting the absorption of dietary fat
- Arena Pharmaceuticals: Arena Pharmaceuticals is a US-based biopharmaceutical company that markets Belviq XR (lorcaserin extended-release), an oral weight-loss drug that works by suppressing appetite
- Vivus: Vivus is a US-based pharmaceutical company that markets Qsymia (phentermine/topiramate), an oral weight loss drug that works by suppressing appetite and reducing food cravings
These companies are among the major players in the US obesity drugs market, but there are also many other companies developing and marketing obesity drugs. The market is highly competitive, with companies competing on factors such as efficacy, safety, and pricing.
Healthcare Policies and Regulatory Landscape
The US healthcare policies and regulatory landscape play a critical role in the development and marketing of obesity drugs. Here are some key policies and regulations that impact the US obesity drugs market:
- FDA Approval: All prescription obesity drugs marketed in the US must receive approval from the US Food and Drug Administration (FDA). The FDA evaluates drugs for safety and efficacy based on clinical trial data and other evidence
- Drug Scheduling: Some obesity drugs, such as phentermine and topiramate, are classified as controlled substances by the Drug Enforcement Administration (DEA) and are subject to additional regulations and restrictions
- Insurance Coverage: Insurance coverage for obesity drugs varies depending on the specific drug, the insurance plan, and the patient's individual circumstances. In general, insurance coverage for obesity drugs may be limited, and patients may need to meet certain criteria to be eligible for coverage
- Medicare Coverage: Medicare covers some obesity drugs for eligible beneficiaries who meet certain criteria. However, coverage is limited, and patients may need to pay a portion of the cost of the drug
- Pricing and Reimbursement: The pricing of obesity drugs is subject to regulatory oversight and reimbursement policies. Drug companies must navigate complex pricing and reimbursement systems, which can impact the profitability of their products
- Clinical Practice Guidelines: Clinical practice guidelines for the treatment of obesity may impact the use of obesity drugs in clinical practice. These guidelines are developed by professional organizations and provide recommendations for the management of obesity
Overall, the regulatory landscape for obesity drugs in the US is complex and can impact the development, marketing, and use of these drugs. Companies must navigate these regulations and policies to bring their products to market, while healthcare providers and patients must consider these factors when making treatment decisions.
1. Report Description of the US Obesity Drugs Market
1.1 Research Scope and Assumption
1.2 Objective of the study
1.3 Research Methodology
1.4 Reason to buy the report
2. US Obesity Drugs Market Executive Summary
2.1 US Obesity Drugs Market – Industry Snapshot & key buying criteria, 2022-2030
2.2 Market Size, Growth Prospects, and Key findings
3. Market Dynamics of the US Obesity Drugs Market
3.1 Market Growth Drivers Analysis
3.2 Market Restrains Analysis
4. US Obesity Drugs Market Segmentation
4.1 By Drug Type
4.1.1 Bupropion & Naltrexone
4.1.2 Orlistat
4.1.3 Lorcaserin
4.1.4 Phentermine
4.1.5 Topiramate
4.1.6 Liraglutide
4.2 By Distribution Channel
4.2.1 Hospital Pharmacies
4.2.2 Retail Pharmacies
4.2.3 E-commerce
5. US Obesity Drugs Market Share
5.1 Market Analysis, Insights, and Forecast – By Revenue
6. Competitive Landscape
6.1 Major Top Market Players
7. Key Company Profiles
7.1 Company 1
7.1.1 Overview
7.1.2 Financial Performance
7.1.3 Product & Services
7.1.4 Strategic initiatives
7.2 Company 2
7.2.1 Overview
7.2.2 Financial Performance
7.2.3 Product & Services
7.2.4 Strategic initiatives
7.3 Company 3
7.3.1 Overview
7.3.2 Financial Performance
7.3.3 Product & Services
7.3.4 Strategic initiatives
7.4 Company 4
7.4.1 Overview
7.4.2 Financial Performance
7.4.3 Product & Services
7.4.4 Strategic initiatives
7.5 Company 5
7.5.1 Overview
7.5.2 Financial Performance
7.5.3 Product & Services
7.5.4 Strategic initiatives
8. Healthcare Policies and Regulatory Landscape
8.1 Healthcare Policies in the US
8.2 Regulatory Framework in the US
8.3 Pricing & Reimbursement Scenario in US Obesity Drugs Market
9. Factors Driving Future Growth
9.1 New Trends and Development US Obesity Drugs Market
9.2 Future Opportunities
10. Strategic Recommendations
Obesity Drugs Market Segmentation
By Drug Type
- Bupropion & Naltrexone
- Orlistat
- Lorcaserin
- Phentermine
- Topiramate
- Liraglutide
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- E-commerce
Insights10 will provide you with the reports within 10 key parameters which are:
- Market Overview
- Market Growth Drivers & Restraints
- Epidemiology of Disease Type
- Market Segmentation
- Market Share
- Competitive Landscape
- Key Company Profiles
- Healthcare Policies & Regulatory Framework
- Reimbursement Scenario
- Factors Driving Future Growth
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
(1).png)
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
- Establishing market drivers and trends
- Analyzing the regulatory landscape to understand future growth
- Market Segment based analysis to obtain revenue/volume
- Analyzing current needs and determining penetration to estimate the market
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
- Intelligent insights to take informed business decisions
- Qualitative, acute and result oriented market analysis
- Market size and forecasts from 2022 to 2030
- Opportunities for expansion and in-depth market analysis
- Segmentation and regional revenue forecasts
- Analysis of the market share and competitive landscape
- Strategic Recommendations to chart future course of action
- Comprehensive Market Research Report in PDF and PPT formats
Need more?
- Ask our analyst how this study was put together to learn more
- Discuss additional requirements as part of the free customisation
- Add more countries or regions to the scope
- Get answers to specific business questions
- Develop the business case to launch the product
- Find out how this report may influence your business revenue
Related reports (by category)
Related reports (by geography)
Healthcare Services
US Cancer Pain Management Market Analysis
Pharmaceuticals
US Oncology Therapeutics Market Analysis
Pharmaceuticals
